First-Line Treatment Recommendations for ES-SCLC
Hossein Borghaei, DO, reviews the currently accepted first-line treatment recommendation for extensive-stage small cell lung cancer: a triple combination of carboplatin, etoposide, and a checkpoint inhibitor (atezolizumab or durvalumab). He provides an overview of the IMpower and CASPIAN trials.